- Home
- REE vs CTXR Comparison
REE vs CTXR Comparison
Compare REE & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REE | CTXR |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1M | 16.8M |
| IPO Year | 2021 | 2010 |
Fundamental Metrics
Financial Performance| Metric | REE | CTXR |
|---|---|---|
| Price | $0.53 | $0.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $8.50 | $6.00 |
| AVG Volume (30 Days) | 45.9K | ★ 625.2K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $327.73 | N/A |
| Revenue Next Year | $36,888.82 | $147.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $0.63 |
| 52 Week High | $3.76 | $2.38 |
Technical Indicators
Market Signals| Indicator | REE | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 48.56 | 41.06 |
| Support Level | $0.53 | $0.70 |
| Resistance Level | $0.74 | $0.99 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 46.94 | 6.57 |
Price Performance
Historical ComparisonAbout REE REE Automotive Ltd.
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is in early stages of commercialization and develop and produce software-defined vehicle (SDV) technology that manages vehicle operations and features through proprietarily-developed software. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.